Neogen (NEOG) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 101.2% versus a loss of 85.1%. Neogen is the larger company by market cap ($2.55 billion vs $202.8 million), about 12.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEOG | NNNN |
|---|---|---|
| Share price | $11.71 | $4.62 |
| Market cap | $2.55B | $202.78M |
| 1-day change | +0.26% | -5.71% |
| YTD return | +67.53% | -84.64% |
| 1-year return | +101.20% | -85.09% |
| 5-year return | -71.47% | — |
| P/E ratio (TTM) | — | 30.80 |
| Forward P/E | 30.82 | — |
| EPS (TTM) | $-0.26 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $870.40M | — |
| Revenue growth (YoY) | -2.72% | — |
| Net income (latest FY) | $-7.90M | — |
| Gross margin | 46.93% | — |
| Operating margin | -2.48% | — |
| Net margin | -0.91% | — |
| 52-week high | $14.26 | $44.73 |
| 52-week low | $5.37 | $4.55 |
| Distance from 52-week high | -17.88% | -89.67% |
| Analyst consensus | buy | — |
| Avg. price target upside | +19.56% | — |
| Average volume | 3.14M | 146.84K |
| Shares outstanding | 218.11M | 43.89M |
| Employees | 2,636 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neogen is about 12.6 times larger than Anbio Biotechnology by market value ($2.55B vs $202.78M).
- NEOG has outperformed NNNN by 186.3 percentage points over the past year.
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
NEOG vs NNNN FAQ
Which is bigger, Neogen or Anbio Biotechnology?
Neogen (NEOG) is larger, with a market capitalization of $2.55B compared with $202.78M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NEOG or NNNN?
NEOG returned +101.20% over the past 12 months, compared with -85.09% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Neogen and Anbio Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.